Literature DB >> 16297671

Reflux rising! An essay on witnessing a disease in evolution.

K D Bardhan1, C Royston, A K Nayyar.   

Abstract

BACKGROUND AND AIM: The prevalence of gastro-oesophageal reflux disease is thought to be rising but supporting evidence is sparse. We assessed trends from data prospectively collected over 25 years at our centre which serves Rotherham's 250000 population. PATIENTS AND METHODS: Detailed computerised records have been kept of all patients investigated for upper gastrointestinal symptoms. DEFINITION: Erosive oesophagitis=endoscopy-verified erosive changes. Non-erosive reflux=heartburn+/-regurgitation but normal endoscopy. Gastro-oesophageal reflux disease=erosive oesophagitis+non-erosive reflux, i.e. total.
RESULTS: The data, presented in 5-year time periods spanning 1977-2001, showed four major changing trends. (1) The numbers with newly diagnosed gastro-oesophageal reflux disease rose markedly, affecting both erosive oesophagitis and non-erosive reflux. Gastro-oesophageal reflux disease: n=714; 1587; 2381; 3812; 3880. (2) The proportion of women affected rose from 0.36 to 0.82. (3) Gastro-oesophageal reflux disease patients were older than the general population; the mean age at presentation rose from 48.0 to 53.5 years. (4) Presentation with haemorrhage (percentage of erosive oesophagitis) rose from 5.2% to 10.9% but, as with stricture (around 4%), remained uncommon. Throughout, few (4.4%) changed from non-erosive reflux to erosive oesophagitis.
CONCLUSION: The marked increase in gastro-oesophageal reflux disease cannot be accounted for by greater awareness alone for the demographic profile has changed, or by misclassification as erosive oesophagitis was diagnosed on endoscopic appearances. The dramatic five-fold increase in gastro-oesophageal reflux disease is a new phenomenon, perhaps an example of a disease in evolution.

Entities:  

Mesh:

Year:  2005        PMID: 16297671     DOI: 10.1016/j.dld.2005.10.011

Source DB:  PubMed          Journal:  Dig Liver Dis        ISSN: 1590-8658            Impact factor:   4.088


  6 in total

1.  Treatment of non-erosive reflux disease with a proton pump inhibitor in Chinese patients: a randomized controlled trial.

Authors:  Victoria P Y Tan; Wai M Wong; Ting K Cheung; Kam C Lai; Ivan F N Hung; Pierre Chan; Roberta Pang; Benjamin C Y Wong
Journal:  J Gastroenterol       Date:  2011-05-03       Impact factor: 7.527

2.  Functional heartburn, nonerosive reflux disease, and reflux esophagitis are all distinct conditions--a debate: pro.

Authors:  Tomás Navarro-Rodriguez; Ronnie Fass
Journal:  Curr Treat Options Gastroenterol       Date:  2007-08

3.  Prevalence of dysphagia in patients with gastroesophageal reflux in Germany.

Authors:  Elfriede Bollschweiler; Katharina Knoppe; Eva Wolfgarten; Arnulf H Hölscher
Journal:  Dysphagia       Date:  2008-01-18       Impact factor: 3.438

Review 4.  Reflux esophagitis, high-grade neoplasia, and early Barrett's carcinoma-what is the place of the Merendino procedure?

Authors:  A H Hölscher; D Vallböhmer; C Gutschow; E Bollschweiler
Journal:  Langenbecks Arch Surg       Date:  2008-11-07       Impact factor: 3.445

5.  Nonerosive Reflux Disease (NERD) - An Update.

Authors:  Tiberiu Hershcovici; Ronnie Fass
Journal:  J Neurogastroenterol Motil       Date:  2010-01-31       Impact factor: 4.924

6.  Antireflux surgery is equally beneficial in nonerosive and erosive gastroesophageal reflux disease.

Authors:  Joong-Min Park; Kyong-Choun Chi
Journal:  Ann Surg Treat Res       Date:  2017-07-30       Impact factor: 1.859

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.